Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Proliferative Diabetic Retinopathy (PDR) Market Size Changed, over the years?

The market size for proliferative diabetic retinopathy (PDR) has seen a swift expansion in recent years. The market, which is projected to rise from $2.42 billion in 2024 to $2.7 billion in 2025, boasts a compound annual growth rate (CAGR) of 11.6%. This growth during the historical period is linked to an increase in diabetes incidence, alterations in lifestyle habits and consumption of unhealthy diets, governmental efforts, and a higher count of vision loss related to diabetes.

How Much Will the Proliferative Diabetic Retinopathy (PDR) Market Be Worth in 2029?

The market size for proliferative diabetic retinopathy (PDR) is anticipated to witness swift expansion in the upcoming years, reaching a valuation of $4.02 billion in 2029 with a compound annual growth rate (CAGR) of 10.5%. Factors contributing to growth during that forecasted period encompass an aging populace, increased awareness and education related to diabetes, funding for research and development, and a higher demand for combination therapies. Foreseen trends over this period comprise improvements in diagnostic technologies, development in treatment alternatives, the integration of artificial intelligence (AI) for early diagnosis, advancements in gene therapy, and progressive retinal imaging.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

Which is the Largest Company in the Proliferative Diabetic Retinopathy (PDR) Market?

Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

What Are the Main Market Drivers in the Proliferative Diabetic Retinopathy (PDR) Industry?

The increase in diabetes cases is anticipated to fuel the proliferative diabetic retinopathy (PDR) market’s growth in the future. Diabetes, a long-term medical condition, results in high levels of glucose (sugar) in the blood. Diabetes is the main contributing factor to proliferative diabetic retinopathy disease. There are several treatment strategies to stop further retinal damage and maintain eyesight in people with this condition. For instance, data from the National Health Service (NHS), a UK government agency, revealed that the number of diabetes cases in individuals under 40 grew from 173,166 in 2022 to 216,440 in 2023 as of June 2024. This considerable increase shows a worrying pattern among younger age groups. The given data illustrates the swift increase in diabetes among the younger generation. Thus, the proliferative diabetic retinopathy (PDR) market is being propelled by the increasing prevalence of diabetes.

Key Market Driver for the Proliferative Diabetic Retinopathy (PDR) Market – The Effect of Obesity on Market Expansion

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp

How Is the Proliferative Diabetic Retinopathy (PDR) Market Segments Structured?

The proliferative diabetic retinopathy (PDR) market covered in this report is segmented –

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy

2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations

3) By Application: Hospitals, Clinics, Other Applications

Subsegments:

1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab

2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide

3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation

4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

What Strategic Trends Are Transforming the Proliferative Diabetic Retinopathy (PDR) Market?

The primary entities in the proliferative diabetic retinopathy market are diligently working on the innovation of new therapies aimed at boosting the efficacy of treatments, minimizing the treatment workload and enhancing patient results. For illustration, Biogen, a biotechnology company based in the US, and Samsung Bioepis, a South Korean biotech firm, launched Byooviz (ranibizumab-nuna), the USA’s premier ophthalmology biosimilar, in June 2022. These developed products are designated for the treatment of individuals suffering from diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Which Global Regions Offer the Highest Growth in the Proliferative Diabetic Retinopathy (PDR) Market?

North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

This Report Delivers Insight On:

1. How big is the proliferative diabetic retinopathy (pdr) market, and how is it changing globally?

2. Who are the major companies in the proliferative diabetic retinopathy (pdr) market, and how are they performing?

3. What are the key opportunities and risks in the proliferative diabetic retinopathy (pdr) market right now?

4. Which products or customer segments are growing the most in the proliferative diabetic retinopathy (pdr) market?

5. What factors are helping or slowing down the growth of the proliferative diabetic retinopathy (pdr) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model